IL157075A0 - Novel modified release formulation - Google Patents
Novel modified release formulationInfo
- Publication number
- IL157075A0 IL157075A0 IL15707502A IL15707502A IL157075A0 IL 157075 A0 IL157075 A0 IL 157075A0 IL 15707502 A IL15707502 A IL 15707502A IL 15707502 A IL15707502 A IL 15707502A IL 157075 A0 IL157075 A0 IL 157075A0
- Authority
- IL
- Israel
- Prior art keywords
- matrix former
- modified release
- release formulation
- unit dosage
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0100477A SE0100477D0 (sv) | 2001-02-13 | 2001-02-13 | Novel formulation |
SE0100478A SE0100478D0 (sv) | 2001-02-13 | 2001-02-13 | Novel formulation |
PCT/SE2002/000228 WO2002064121A1 (en) | 2001-02-13 | 2002-02-08 | Novel modified released formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
IL157075A0 true IL157075A0 (en) | 2004-02-08 |
Family
ID=26655389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15707502A IL157075A0 (en) | 2001-02-13 | 2002-02-08 | Novel modified release formulation |
Country Status (19)
Country | Link |
---|---|
US (3) | US20040067256A1 (es) |
EP (2) | EP1368006B1 (es) |
JP (2) | JP2004518709A (es) |
KR (1) | KR20040058103A (es) |
CN (2) | CN1491105A (es) |
AT (1) | ATE324871T1 (es) |
AU (1) | AU2002228579B2 (es) |
BR (1) | BR0206825A (es) |
CA (2) | CA2434835A1 (es) |
DE (1) | DE60211130T2 (es) |
DK (1) | DK1368006T3 (es) |
ES (1) | ES2261643T3 (es) |
HK (1) | HK1059740A1 (es) |
IL (1) | IL157075A0 (es) |
MX (1) | MXPA03007092A (es) |
NO (1) | NO20033564L (es) |
NZ (2) | NZ526994A (es) |
PT (1) | PT1368006E (es) |
WO (2) | WO2002064118A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
AU2003220472A1 (en) * | 2002-09-28 | 2004-04-19 | Mcneil-Ppc, Inc. | Modified release dosage form with two cores |
SE0301904D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | Novel imidazopyridine compound II with therapeutic effect |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
BRPI0414046A (pt) * | 2003-08-29 | 2006-10-24 | Dynogen Pharmaceuticals Inc | método de tratamento de um distúrbio de motilidade gastrintestinal, de tratamento de "gerd", de "gerd" noturno, composição farmacêutica, kit que compreende um composto e método para aumentar a motilidade esofágica em um paciente |
EP1689368B1 (en) * | 2003-12-04 | 2016-09-28 | Bend Research, Inc | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions |
WO2005053652A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
CN1889931A (zh) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾-冻凝方法 |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
SE0303451D0 (sv) * | 2003-12-18 | 2003-12-18 | Astrazeneca Ab | New compounds |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
SI2001445T1 (sl) * | 2006-03-16 | 2015-02-27 | Euro-Celtique S.A. | Farmacevtski sferoidi |
WO2009111648A1 (en) | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
WO2011000126A1 (zh) * | 2009-06-29 | 2011-01-06 | Liu Yu | 脂溶性药物组合物、制备方法及其用途 |
EP3296295A1 (en) | 2009-08-07 | 2018-03-21 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
US20130165880A1 (en) | 2010-09-17 | 2013-06-27 | David T. Amos | Antimicrobial disposable absorbent articles |
US20140037574A1 (en) * | 2010-11-26 | 2014-02-06 | Pius Sedowhe Fasinu | Pharmaceutical composition |
CA2859174C (en) | 2011-12-12 | 2019-03-05 | Orbis Biosciences, Inc. | Sustained release particle formulations |
WO2013090439A1 (en) * | 2011-12-12 | 2013-06-20 | Orbis Biosciences, Inc. | Sustained release particle formulations of guaifenesin |
EP3319595A4 (en) * | 2015-06-30 | 2019-04-03 | Kemin Industries, Inc. | ENCAPSULATED ACTIVE INGREDIENTS FOR REGULATED ENERGETIC RELEASE |
US9889120B2 (en) | 2016-01-14 | 2018-02-13 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
DE102017108054A1 (de) | 2017-04-13 | 2018-10-18 | Natura Werk Gebr. Hiller GmbH & Co. KG | Essbare Zusammensetzung zur Verdauungsförderung |
CN115350184A (zh) | 2020-01-10 | 2022-11-18 | 康圣博施医药有限公司 | 药物的治疗组合以及其使用方法 |
WO2023184282A1 (en) * | 2022-03-30 | 2023-10-05 | Guizhou Sinorda Biomedicine Co., Ltd | X842 formulation |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL248553A (es) * | 1959-02-18 | |||
NL194389C (nl) * | 1984-06-14 | 2002-03-04 | Novartis Ag | Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
US4956182A (en) * | 1989-03-16 | 1990-09-11 | Bristol-Myers Company | Direct compression cholestyramine tablet and solvent-free coating therefor |
US5405617A (en) * | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
US5281420A (en) * | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
NZ270439A (en) * | 1995-02-02 | 1996-04-26 | Bernard Charles Sherman | Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer |
US5851555A (en) * | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
-
2002
- 2002-02-08 CA CA002434835A patent/CA2434835A1/en not_active Abandoned
- 2002-02-08 CA CA002434542A patent/CA2434542A1/en not_active Abandoned
- 2002-02-08 NZ NZ526994A patent/NZ526994A/en unknown
- 2002-02-08 WO PCT/SE2002/000227 patent/WO2002064118A1/en not_active Application Discontinuation
- 2002-02-08 AU AU2002228579A patent/AU2002228579B2/en not_active Ceased
- 2002-02-08 WO PCT/SE2002/000228 patent/WO2002064121A1/en active IP Right Grant
- 2002-02-08 KR KR10-2003-7010577A patent/KR20040058103A/ko active IP Right Grant
- 2002-02-08 JP JP2002563916A patent/JP2004518709A/ja active Pending
- 2002-02-08 US US10/467,900 patent/US20040067256A1/en not_active Abandoned
- 2002-02-08 MX MXPA03007092A patent/MXPA03007092A/es active IP Right Grant
- 2002-02-08 IL IL15707502A patent/IL157075A0/xx unknown
- 2002-02-08 BR BR0206825-7A patent/BR0206825A/pt not_active IP Right Cessation
- 2002-02-08 EP EP02710645A patent/EP1368006B1/en not_active Expired - Lifetime
- 2002-02-08 AT AT02710645T patent/ATE324871T1/de not_active IP Right Cessation
- 2002-02-08 JP JP2002563914A patent/JP2004518708A/ja active Pending
- 2002-02-08 US US10/467,723 patent/US20040067252A1/en not_active Abandoned
- 2002-02-08 PT PT02710645T patent/PT1368006E/pt unknown
- 2002-02-08 DK DK02710645T patent/DK1368006T3/da active
- 2002-02-08 DE DE60211130T patent/DE60211130T2/de not_active Expired - Fee Related
- 2002-02-08 CN CNA028049063A patent/CN1491105A/zh active Pending
- 2002-02-08 CN CNA028049144A patent/CN1491104A/zh active Pending
- 2002-02-08 ES ES02710645T patent/ES2261643T3/es not_active Expired - Lifetime
- 2002-02-08 NZ NZ526993A patent/NZ526993A/en unknown
- 2002-02-08 EP EP02711597A patent/EP1361868A1/en not_active Withdrawn
-
2003
- 2003-08-12 NO NO20033564A patent/NO20033564L/no not_active Application Discontinuation
-
2004
- 2004-04-15 HK HK04102657A patent/HK1059740A1/xx not_active IP Right Cessation
-
2007
- 2007-05-14 US US11/748,366 patent/US20080118560A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2261643T3 (es) | 2006-11-16 |
JP2004518709A (ja) | 2004-06-24 |
DK1368006T3 (da) | 2006-07-24 |
EP1368006A1 (en) | 2003-12-10 |
EP1368006B1 (en) | 2006-05-03 |
US20040067252A1 (en) | 2004-04-08 |
ATE324871T1 (de) | 2006-06-15 |
DE60211130T2 (de) | 2006-11-30 |
CA2434542A1 (en) | 2002-08-22 |
US20080118560A1 (en) | 2008-05-22 |
MXPA03007092A (es) | 2003-11-18 |
CN1491104A (zh) | 2004-04-21 |
CN1491105A (zh) | 2004-04-21 |
WO2002064121A1 (en) | 2002-08-22 |
CA2434835A1 (en) | 2002-08-22 |
JP2004518708A (ja) | 2004-06-24 |
EP1361868A1 (en) | 2003-11-19 |
HK1059740A1 (en) | 2004-07-16 |
DE60211130D1 (de) | 2006-06-08 |
NO20033564D0 (no) | 2003-08-12 |
PT1368006E (pt) | 2006-08-31 |
BR0206825A (pt) | 2004-02-25 |
WO2002064118A1 (en) | 2002-08-22 |
NZ526994A (en) | 2005-01-28 |
NO20033564L (no) | 2003-10-02 |
KR20040058103A (ko) | 2004-07-03 |
AU2002228579B2 (en) | 2006-07-27 |
NZ526993A (en) | 2005-01-28 |
US20040067256A1 (en) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL157075A0 (en) | Novel modified release formulation | |
JP3805797B2 (ja) | N−ピペリジノ−3−ピラゾールカルボキサミド誘導体、その塩およびそれらの溶媒和物の経口投与用医薬組成物 | |
US6531153B2 (en) | Composition with sustained release of levodopa and carbidopa | |
US6635278B1 (en) | Pharmaceutical formulations | |
WO2004012700A3 (en) | Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release | |
WO2007061415A1 (en) | Pharmaceutical compositions of telmisartan | |
DK170793B1 (da) | Dispergerbar lægemiddelformulering og fremgangsmåde til fremstilling heraf | |
MX2010008711A (es) | Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada. | |
US6833478B2 (en) | N,N-dinitramide salts as solubilizing agents for biologically active agents | |
CA2435714C (en) | Fenofibrate tablets | |
CA2067733C (en) | Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure | |
KR20110115592A (ko) | 피리도피리미디논의 고체 경구 제제 | |
AU759869B2 (en) | Pharmaceutical formulations | |
AU3283100A (en) | Controlled-release compositions of betahistine | |
KR20240011873A (ko) | 분산성 조성물 | |
KR19990023194A (ko) | 라세미화 반응에 대하여 안정화된 실란세트론 제제 | |
KR100884685B1 (ko) | 신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제 | |
CA2520813A1 (en) | Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists | |
JPH05310570A (ja) | 粒状製剤 | |
ZA200309710B (en) | Pharmaceutical formulation containing an LTB4 antagonist. |